{"classes":[{"categories":[{"measurements":[{"comment":"KM estimate at Year 5 was NA due to insufficient patients and/or follow-up. 95% CIs were NA due to insufficient patients and/or follow-up.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The upper 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG001","lowerLimit":"81.5","upperLimit":"NA","value":"81.5"},{"comment":"KM estimate at Year 4 was NA due to insufficient patients and/or follow-up. The upper 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG002","lowerLimit":"21.0","upperLimit":"NA","value":"NA"},{"comment":"KM estimate at Year 4 was NA due to insufficient patients and/or follow-up. The upper 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG003","lowerLimit":"34.4","upperLimit":"NA","value":"NA"},{"comment":"KM estimate at Year 4 was NA due to insufficient patients and/or follow-up. The upper 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG004","lowerLimit":"68.5","upperLimit":"NA","value":"NA"},{"comment":"KM estimate at Year 4 was NA due to insufficient patients and/or follow-up. 95% CIs were NA due to insufficient patients and/or follow-up.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"KM estimate at Year 4 was NA due to insufficient patients and/or follow-up. 95% CIs were NA due to insufficient patients and/or follow-up.","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The upper 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG007","lowerLimit":"14.6","upperLimit":"NA","value":"33.4"},{"comment":"The upper 95% CI was NA due to insufficient patients and/or follow-up.","groupId":"OG008","lowerLimit":"9.4","upperLimit":"NA","value":"11.2"},{"groupId":"OG009","lowerLimit":"4.1","upperLimit":"17.4","value":"8.9"},{"groupId":"OG010","lowerLimit":"1.3","upperLimit":"7.6","value":"3.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"50"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"49"},{"groupId":"OG007","value":"30"},{"groupId":"OG008","value":"36"},{"groupId":"OG009","value":"28"},{"groupId":"OG010","value":"24"}],"units":"Participants"}],"description":"OS was based on Kaplan-Meier method. Survival was defined as the time period from the date of first dose of bosutinib to the date of death or date of last contact for those censored.\n\nNA = not estimable. One year = 12 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG000","title":"Bosutinib 500 mg, CP2L-CML IM-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG001","title":"Bosutinib 500 mg, CP2L-CML IM-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I, D and NI R/I or IM R/I and NI-I CML.","id":"OG002","title":"Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-R CML.","id":"OG003","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-I CML.","id":"OG004","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and NI-R CML.","id":"OG005","title":"Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with AP IM R/I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG006","title":"Bosutinib 500 mg, AP-CML IM R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with AP Multi-TKI: IM, D and/or NI R/I CML.","id":"OG007","title":"Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with BP IM R/I CML ; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG008","title":"Bosutinib 500 mg, BP-CML IM R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with BP Multi-TKI: IM, D and/or NI R/I CML.","id":"OG009","title":"Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with Ph+ ALL","id":"OG010","title":"Bosutinib 500 mg, Ph+ ALL (Part 2)"}],"paramType":"MEDIAN","populationDescription":"All-treated population included all enrolled participants who received at least 1 dose of study medication.","reportingStatus":"POSTED","timeFrame":"Years 1, 2, 3, 4, and 5 (CP2L only)","title":"Overall Survival (OS) - Part 2","type":"SECONDARY","unitOfMeasure":"Months"}